CN1255105C - 齐拉西酮及其盐的水溶性包合物及其制备方法 - Google Patents

齐拉西酮及其盐的水溶性包合物及其制备方法 Download PDF

Info

Publication number
CN1255105C
CN1255105C CNB021551391A CN02155139A CN1255105C CN 1255105 C CN1255105 C CN 1255105C CN B021551391 A CNB021551391 A CN B021551391A CN 02155139 A CN02155139 A CN 02155139A CN 1255105 C CN1255105 C CN 1255105C
Authority
CN
China
Prior art keywords
ziprasidone
inclusion compound
preparation
cyclodextrin
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB021551391A
Other languages
English (en)
Chinese (zh)
Other versions
CN1424037A (zh
Inventor
瞿文
包泳初
陈庆华
朱宝泉
隋强
王小妹
时惠麟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Pharmaceutical Industry
Original Assignee
Shanghai Institute of Pharmaceutical Industry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Pharmaceutical Industry filed Critical Shanghai Institute of Pharmaceutical Industry
Priority to CNB021551391A priority Critical patent/CN1255105C/zh
Publication of CN1424037A publication Critical patent/CN1424037A/zh
Priority to PCT/CN2003/000979 priority patent/WO2004054621A1/fr
Priority to AU2003303019A priority patent/AU2003303019A1/en
Application granted granted Critical
Publication of CN1255105C publication Critical patent/CN1255105C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB021551391A 2002-12-17 2002-12-17 齐拉西酮及其盐的水溶性包合物及其制备方法 Expired - Fee Related CN1255105C (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CNB021551391A CN1255105C (zh) 2002-12-17 2002-12-17 齐拉西酮及其盐的水溶性包合物及其制备方法
PCT/CN2003/000979 WO2004054621A1 (fr) 2002-12-17 2003-11-18 Clathrates hydrosolubles de ziprasidone et de ses sels et procedes de preparation associes
AU2003303019A AU2003303019A1 (en) 2002-12-17 2003-11-18 Water-soluble clathrates of ziprasidone and its salts, and the preparation methods therefor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB021551391A CN1255105C (zh) 2002-12-17 2002-12-17 齐拉西酮及其盐的水溶性包合物及其制备方法

Publications (2)

Publication Number Publication Date
CN1424037A CN1424037A (zh) 2003-06-18
CN1255105C true CN1255105C (zh) 2006-05-10

Family

ID=4752571

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB021551391A Expired - Fee Related CN1255105C (zh) 2002-12-17 2002-12-17 齐拉西酮及其盐的水溶性包合物及其制备方法

Country Status (3)

Country Link
CN (1) CN1255105C (fr)
AU (1) AU2003303019A1 (fr)
WO (1) WO2004054621A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016325A2 (fr) 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd. Chlorhydrate de ziprasidone cristallin et ses procedes de preparation
WO2005040160A2 (fr) 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Procedes de preparation de ziprasidone
CA2500667C (fr) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Synthese de sels d'addition acide de ziprasidone et de produits intermediaires connexes au moyen de reactions solide-gaz
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
US20130108701A1 (en) 2010-05-25 2013-05-02 Krishna Murthy Bhavanasi Solid Dosage Forms of Antipsychotics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
PH31594A (en) * 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей

Also Published As

Publication number Publication date
AU2003303019A1 (en) 2004-07-09
WO2004054621A1 (fr) 2004-07-01
CN1424037A (zh) 2003-06-18

Similar Documents

Publication Publication Date Title
Aytac et al. Fast-dissolving electrospun gelatin nanofibers encapsulating ciprofloxacin/cyclodextrin inclusion complex
CN1424112A (zh) 难溶性药物的水溶性包合物及其制备方法
CA2071623C (fr) Composition a base de cyclodextrine
SK282032B6 (sk) Kompozícia na báze solí arylheterocyklických zlúčenín
EP2019664B1 (fr) Composition pharmaceutique stable contenant du docétaxel et son procédé de préparation
CN1255105C (zh) 齐拉西酮及其盐的水溶性包合物及其制备方法
CN113197872B (zh) 一种稳定性改善的丁苯酞口服冻干粉及其制备方法和用途
CN1355801A (zh) 噻唑烷二酮衍生物及其作为抗糖尿病药的用途
CN1923285A (zh) 含有至少两种活性成分的注射用无菌药物制剂
JP2013525385A (ja) ペクチン−アドリアマイシン共役体の凍結乾燥製剤および製造方法
US11517569B2 (en) Vilazodone inclusion complexes, compositions and preparation thereof
CN1568999A (zh) 稳定的医药用河豚毒素冷冻干燥制剂
JP2017518985A (ja) アリサルタン・イソプロキシル固体分散体及び医薬組成物
Wu et al. Amorphous silibinin nanoparticles loaded into porous starch to enhance remarkably its solubility and bioavailability in vivo
de Araújo et al. Synthesis, characterization and cytotoxic evaluation of inclusion complexes between Riparin A and β-cyclodextrin
US20070249720A1 (en) Thiourea Derivative-Containing Pharmaceutical Composition Having Improved Solubility and Bioavailability
CN1268337C (zh) 地氯雷他定干混悬剂及其制备方法
Rahimi et al. Aqueous stability of leuprolide acetate: Effect of temperature, dissolved oxygen, pH and complexation with β-cyclodextrin
CN1853627A (zh) 双苯并异硒唑乙烷环糊精或环糊精衍生物包合物及其制备方法和其用途
CN1739537A (zh) 灯盏花素环糊精包合物及其制剂
CA2897330C (fr) Complexes d'inclusion de voriconazole
CN106580895A (zh) 含盐酸维拉佐酮固体分散体的口腔崩解片及其制备方法
CN117771191A (zh) 一种盐酸雷莫司琼注射冻干粉及其制备方法
KR20080002313A (ko) 용출율이 향상된 시부트라민 함유 경구투여용 약제 조성물
CN102008734A (zh) 一种α晶型伊马替尼的包合物及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060510

Termination date: 20141217

EXPY Termination of patent right or utility model